Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?Zacks Investment Research • 03/27/26
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/26/26
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 TranscriptSeeking Alpha • 03/25/26
Sarepta Therapeutics' experimental siRNA therapies show promising early resultsProactive Investors • 03/25/26
Sarepta Surges As It Takes On Novartis' $12 Billion Muscular Dystrophy BuyoutInvestors Business Daily • 03/25/26
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?24/7 Wall Street • 03/25/26
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1Business Wire • 03/25/26
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1Business Wire • 03/24/26
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD TherapiesZacks Investment Research • 03/20/26
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety StudyZacks Investment Research • 03/17/26
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with DuchenneBusiness Wire • 03/16/26
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship ProgramBusiness Wire • 02/27/26
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/26/26
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific CongressBusiness Wire • 02/26/26
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 02/25/26